Welcome to our dedicated page for Grail news (Ticker: GRAL), a resource for investors and traders seeking the latest updates and insights on Grail stock.
About GRAIL Inc.
GRAIL Inc. (Nasdaq: GRAL) is a pioneering healthcare company dedicated to transforming cancer detection through innovative diagnostic solutions. Headquartered in Menlo Park, California, with additional locations in Washington, D.C., North Carolina, and the United Kingdom, GRAIL's mission is to detect cancer early, when it can be cured. The company leverages cutting-edge next-generation sequencing (NGS), advanced machine learning algorithms, and large-scale clinical studies to develop multi-cancer early detection (MCED) technologies that address some of the most challenging gaps in cancer screening today.
Core Technology and Products
At the heart of GRAIL's offerings is its Galleri® multi-cancer early detection test. This groundbreaking blood-based test identifies DNA shed by cancer cells, known as methylation patterns, to detect a wide range of cancers at earlier stages, including those that currently lack recommended screening protocols. By pinpointing the cancer signal's origin, Galleri provides healthcare providers with actionable insights to guide diagnostic and treatment pathways. The test is designed to complement existing cancer screenings, such as mammograms and colonoscopies, and is recommended for adults aged 50 and older or those with elevated cancer risks.
Clinical Validation and Studies
GRAIL has established itself as a leader in clinical validation through its robust portfolio of large-scale studies, including the PATHFINDER, NHS-Galleri, and REFLECTION trials. These studies, conducted in collaboration with leading healthcare institutions and government health systems, aim to assess the safety, performance, and real-world impact of the Galleri test. For example, the PATHFINDER 2 study enrolled over 35,000 participants in the United States, while the NHS-Galleri trial included more than 140,000 participants in the United Kingdom. These efforts underscore GRAIL’s commitment to generating comprehensive clinical evidence to support regulatory approvals and broaden access to its technologies.
Market Applications and Partnerships
GRAIL's innovations extend beyond diagnostics into the broader realm of precision oncology. Its targeted methylation-based platform supports applications such as minimal residual disease detection, biomarker subtyping, and treatment monitoring. The company collaborates with biopharmaceutical firms, including partnerships with AstraZeneca and Daiichi Sankyo, to integrate its technologies into clinical trials and companion diagnostics. Additionally, GRAIL has secured agreements with major health systems, insurers like TRICARE, and employers to expand access to its Galleri test, demonstrating its growing influence in healthcare delivery.
Industry Significance
Operating at the intersection of biotechnology and healthcare, GRAIL addresses a critical unmet need: the early detection of cancers that are often diagnosed at advanced stages. Its focus on leveraging population-scale data, automation, and machine learning positions it as a key player in the evolving landscape of precision medicine. By reducing the incidence of late-stage cancer diagnoses, GRAIL aims to alleviate the global burden of cancer and improve patient outcomes. The company’s emphasis on health equity, as evidenced by its inclusion of diverse populations in clinical trials, further highlights its commitment to making advanced diagnostics accessible to all.
GRAIL announced the first patient testing in the global TROPION-Lung12 Phase 3 study using their Non-Small Cell Lung Cancer (NSCLC) ctDNA Assay. The study, conducted under FDA approval, evaluates adjuvant treatments in Stage I adenocarcinoma NSCLC patients. The trial is sponsored by AstraZeneca in collaboration with Daiichi Sankyo.
GRAIL's blood-based methylation platform detects ctDNA without requiring tissue analysis, streamlining integration into clinical trials. Patients will be screened pre-surgery to determine eligibility for post-surgery treatment. This marks one of the first uses of ctDNA assay in early-stage lung cancer trials to identify patients who may benefit from additional treatment.
GRAIL (GRAL) reported Q3 2024 financial results with total revenue of $28.7 million, up 38% year-over-year. Galleri revenue grew 52% to $25.4 million, with over 250,000 tests sold since launch. The company posted a net loss of $(125.7) million, including $34.6 million in amortization and $19.0 million in restructuring charges. Gross loss was $(22.2) million, while adjusted gross profit reached $11.8 million. The company maintains a strong cash position of $853.6 million, providing runway into 2028.
GRAIL (Nasdaq: GRAL) has announced its upcoming participation at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York. The company's management will deliver a presentation on Thursday, November 21 at 11:00 a.m. ET. The event will be accessible via live and replay webcasts through GRAIL's investor relations website section at investors.grail.com, with recordings available for at least 30 days following the presentation.
GRAIL (Nasdaq: GRAL) has scheduled the release of its third quarter 2024 financial results after market close on Tuesday, November 12, 2024. The company will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and business progress. Interested parties can access the live webcast and replay through the investor relations section at investors.grail.com, with registration available at the provided link. Participants are advised to register and join ten minutes before the scheduled start time.
GRAIL announced initial results from the REFLECTION study evaluating the Galleri® multi-cancer early detection (MCED) test in veterans. The study, conducted across seven VA sites, showed a cancer signal detection rate of 1.30% (37/2854 participants) among veterans with toxic exposure, consistent with other populations. Of 28 participants completing 180-day follow-up, 12 cancer diagnoses were confirmed, with over half identified at early stages (I-III). The test demonstrated a positive predictive value of 42.9%. The study included veterans aged ≥22 years (mean age 60), with 70% exposed to toxic hazards during service. Lung cancer was the most common cancer signal detected.
GRAIL, Inc. (Nasdaq: GRAL) has announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Krevans will serve on the Board's Audit, Compensation, and Nominating and Governance Committees. With her addition, the Board now consists of five directors, four of whom are independent.
Krevans served as president and CEO of Sutter Health from 2016 to 2022, overseeing an integrated network of 14,000 clinicians, 24 hospitals, and various healthcare services. Her leadership focused on advancing clinical programs, innovation, and digital health to improve patient accessibility.
Bob Ragusa, CEO of GRAIL, expressed confidence in Krevans' ability to bring valuable experience to GRAIL's mission of establishing a new standard for multi-cancer early detection. Krevans' extensive healthcare background includes executive roles at Kaiser Permanente and in Maine's healthcare administration. She holds master's degrees in business administration and public health from UC Berkeley and has been recognized as one of the top healthcare leaders by Modern Healthcare.
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company focused on early cancer detection, has announced the granting of equity awards to 55 recently hired non-executive employees. These awards, in the form of restricted stock units (RSUs) totaling 182,223 shares of GRAIL's common stock, were granted under the company's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs are designed to vest over approximately four years, with 25% vesting in either May or August 2025, depending on the employee's start date, and the remaining vesting annually thereafter. This vesting schedule is subject to continued employment with GRAIL or its subsidiaries.
GRAIL, Inc. (Nasdaq: GRAL) has published findings on the performance of its Galleri® multi-cancer early detection (MCED) test for prostate cancer in JCO Precision Oncology. The data, from the CCGA and PATHFINDER studies, show that Galleri preferentially detects aggressive, clinically significant prostate cancers over slow-growing cases.
Key findings include:
- 93% of detected prostate cancers were intermediate or high grade
- 67% were stage III or IV
- Cancer signal of origin prediction accuracy was >90%
- No low-grade cancers were detected
- Only 4.2% of stage I and II cancers were detected
These results suggest that Galleri could be valuable in population-based screening programs without contributing to overdiagnosis of indolent prostate cancers.
GRAIL, a healthcare company focused on early cancer detection, announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's management will present on September 4, 2024, at 3:20 p.m. ET. Investors and interested parties can access both live and replay webcasts of the presentation through GRAIL's investor relations website at investors.grail.com. The webcast will remain available for replay for at least 30 days after the event, providing an opportunity for those unable to attend live to catch up on GRAIL's latest updates and insights.
GRAIL (Nasdaq: GRAL) reported Q2 2024 financial results, showing 43% year-over-year revenue growth to $32.0 million. The company faced a net loss of $1.59 billion, including a $1.42 billion goodwill and intangible impairment. GRAIL's adjusted gross profit increased 66% to $16.0 million, while adjusted EBITDA was $(139.4) million.
Key highlights include enrollment in the REACH study, completion of PATHFINDER 2 study enrollment, and final study visits for the NHS-Galleri trial. GRAIL announced a strategic restructuring, reducing headcount by 30% and focusing on core multi-cancer early detection priorities. These measures are expected to extend the company's cash runway into 2028 and reduce burn to $325 million in 2025.
FAQ
What is the current stock price of Grail (GRAL)?
What is the market cap of Grail (GRAL)?
What is GRAIL Inc.'s primary mission?
What is the Galleri test?
How does GRAIL differentiate itself in the healthcare industry?
What are some key clinical studies conducted by GRAIL?
Who can benefit from the Galleri test?
What industries does GRAIL collaborate with?
What is GRAIL's approach to health equity?
What regulatory steps has GRAIL taken for the Galleri test?
